Discovery of LFF571: an investigational agent for Clostridium difficile infection - Wikidata - wikimedia - TriplyDB

Discovery of LFF571: an investigational agent for Clostridium difficile infection

Discovery of LFF571: an investigational agent for Clostridium difficile infection

http://www.wikidata.org/entity/Q27677144

about

HUMAN MICROBIOTA. Small molecules from the human microbiota Thiopeptide antibiotics: retrospective and recent advances Targeting Antibiotic Resistance The potential for emerging therapeutic options for Clostridium difficile infection A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics.Investigational antimicrobial agents of 2013.Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.Codon randomization for rapid exploration of chemical space in thiopeptide antibiotic variants.Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.Heterologous expression of the thiopeptide antibiotic GE2270 from Planobispora rosea ATCC 53733 in Streptomyces coelicolor requires deletion of ribosomal genes from the expression construct.Binaphthyl-1,2,3-triazole peptidomimetics with activity against Clostridium difficile and other pathogenic bacteria.Clostridium difficile drug pipeline: challenges in discovery and development of new agents Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571 A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.Elucidating and engineering thiopeptide biosynthesis.Single domain antibody coated gold nanoparticles as enhancer for Clostridium difficile toxin detection by electrochemical impedance immunosensors.In Vitro Biosynthesis of the Core Scaffold of the Thiopeptide Thiomuracin Saturation mutagenesis of TsrA Ala4 unveils a highly mutable residue of thiostrepton A.Thiostrepton Variants Containing a Contracted Quinaldic Acid Macrocycle Result from Mutagenesis of the Second Residue.Novel avenues for Clostridium difficile infection drug discovery.Prospects for new antibiotics: a molecule-centered perspective.Therapy of Clostridium difficile infection: perspectives on a changing paradigm.Thiopeptide engineering: a multidisciplinary effort towards future drugs.Natural product and natural product derived drugs in clinical trials.Natural products as probes in pharmaceutical research.Bioactive natural products from novel microbial sources.Elfamycins: inhibitors of elongation factor-Tu.Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.Using bacterial genomes and essential genes for the development of new antibiotics.Post-translational modifications involved in the biosynthesis of thiopeptide antibiotics.New antibiotics in clinical trials for Clostridium difficile.Novel Chalcone-Thiazole Hybrids as Potent Inhibitors of Drug Resistant Staphylococcus aureus.Synthesis of the heterocyclic core of the D-series GE2270.Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.Efficacy of LFF571 in a hamster model of Clostridium difficile infection.Synthesis of Triarylpyridines in Thiopeptide Antibiotics by Using a C-H Arylation/Ring-Transformation Strategy.In vitro antibacterial activities of a thiazolyl peptide antibiotic PM2409.Miyaura borylation/Suzuki-Miyaura coupling (MBSC) sequence of 4-bromo-2,4'-bithiazoles with halides: straightforward access to a heterocylic cluster of d-series of thiopeptide GE2270.

P2860

Q26799980-09E46B4E-FC42-4D6D-92F8-E11B1BF0F6F6 Q26852567-9078C3B8-79D6-492A-9BB2-CC2EE0780DDF Q28078130-A5DD02FF-AFA9-41BE-AEB1-ABDEA803A3A4 Q28082059-38901547-2D28-430B-B2A7-19B70F3D6B4C Q34181822-49C9F9E1-2298-4CE0-B0C7-808F0EEDA17A Q34375204-2992DC12-542B-4AD5-9776-2125724F4BB6 Q34455320-3DE9FF08-DDB0-462C-8E5F-2B9E3757ECB3 Q34520644-12BB73AE-847A-483B-93F8-ACCD6CC33E04 Q35044119-8A1D2F52-8D4F-4FAA-B1F0-4ACCF57E4CCC Q35076880-86CE2A0F-BEC5-4B54-A481-2C94DA097EBD Q35111952-03A8F191-A6FD-4A55-9C64-91BC3709FAF7 Q35611260-09A01B55-914C-499D-9559-FAF180E4EC74 Q35846436-0C017874-59A1-4300-B90D-8E26B5A70CB1 Q36171778-C1A2F15E-328A-49E8-A91A-3B0F161A560C Q36364170-E797252E-FFE1-479D-9273-D6DF7138797D Q36369930-D4CBE609-E828-4877-BD67-3A9AE6F85916 Q36446520-C0C4BB72-23B9-4DAD-951C-EBB0FA90CD53 Q36761831-D6B00B83-52FE-4298-8F0F-A5ABA1041869 Q36781888-28DE0E2E-EFC6-4F87-A516-8CC8337152C9 Q36843584-5D6D5F99-329F-49CA-9B90-01F6E14CEEFA Q38083297-B0B54E44-B5B3-4C49-AB86-CE0C05668E24 Q38113689-3BFC8F0C-10A6-4590-92BE-7DFB079CDD3C Q38139991-6E269915-CC78-4422-A849-DFCA3738B066 Q38214833-330A1F9C-0AC9-487D-9944-5E442BDFF578 Q38247457-05C7978B-FD0B-4B1A-9BAE-5FDFB694E9A4 Q38599715-89E6D4E7-6588-4380-AF8E-2B6C95C4EED8 Q38618414-72BFFB34-1770-456C-866D-3D4D70222A8B Q38657231-C605E59F-5841-40E8-8F2C-E552EDF1D231 Q38719092-7EF0F86B-B2FB-4288-A2DB-6F76746DE02C Q38751212-41373344-CE9C-46A7-89A1-BDF70B170281 Q39035296-A6C8B9E3-9074-4D4E-97AE-0F707229A2B0 Q39208551-CF322E13-0FBB-4984-8FB8-BA3B9EA719AD Q40615409-C765803E-3754-430A-82B8-68A083C70DCB Q40718746-5C9293E9-766E-4ADF-B9DD-0110E828BE2D Q41147861-A720CE3F-8AE8-4251-B62F-9D0DD4414864 Q42274443-798E3243-1165-411F-B6D7-672E9905088D Q42280743-4C8E9218-0BD1-4C37-8A9A-66F76171C2B1 Q48249421-78CF9FBD-9E1D-4A97-A8A3-67211E9D4EBE Q48294895-7584CCAD-466D-4024-B076-9BE018E55834 Q48553246-7C55AA91-63AB-44A2-BC7E-54A32D0B3385

P2860

Discovery of LFF571: an investigational agent for Clostridium difficile infection

http://www.wikidata.org/entity/Q27677144

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@ast

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@en

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@nl

type

label

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@ast

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@en

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@nl

prefLabel

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@ast

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@en

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@nl

P1433

Q27677144-DA8DF499-BD3E-4684-AF88-506DED3F308A

P1476

Q27677144-B4FA513C-9194-48D5-B4BB-CFDE65F58BB0

P2093

Q27677144-06548296-0140-464B-A08F-835E3ED59402

Q27677144-0CAA0262-ECA4-47CA-B9B4-D759CBEF2EC3

Q27677144-223DE01C-84AA-41D3-93F8-76854E35D573

Q27677144-2977F832-816D-42E1-8D1B-3DE6ACD009BB

Q27677144-36D49A28-ACF0-44EE-A31C-140C5C4266D3

Q27677144-37560BCB-6E1C-4846-85C5-18417FC274C7

Q27677144-37EC0AF6-A4A0-4E84-9CE4-3BCEC5327645

Q27677144-3D725B69-90FB-4CEE-A0C4-402552C06D9D

Q27677144-54E45052-2F38-422F-8621-8D7AF21A2873

Q27677144-5D420BBC-C5F6-4C3B-B184-CF0D54854501

P304

Q27677144-FCA13ACA-E2E9-4588-BB69-308AE116889B

P31

Q27677144-37BC80FA-F76C-4E06-9FFF-4620928A639E

P3181

Q27677144-AE943488-3C7B-4307-91A3-416D0BC3DA27

P356

Q27677144-5042CFE7-5783-4004-9B37-9634B563D344

P407

Q27677144-DAEB1C38-3FF9-40BB-B5D8-A09429143D0B

P433

Q27677144-8148DCD5-150D-4CC7-848B-F981265A7515

P478

Q27677144-D8BA0882-23CE-4963-8DF5-500D1B4A7895

P50

Q27677144-09A6C116-5F73-4BD2-8104-4680988AEE0F

P577

Q27677144-2397F8F3-4F8D-4B5E-AC08-F400A6CE525D

P698

Q27677144-EF796618-B7A9-4CBF-88A7-67313BF35C23

P921

Q27677144-C0E243AD-58EE-4204-80F5-5A744144ED87

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of LFF571: an investigational agent for Clostridium difficile infection

@en

P2093

Adam Amaral

http://www.w3.org/2001/XMLSchema#string

Akash Jain

http://www.w3.org/2001/XMLSchema#string

Anna Trzasko

http://www.w3.org/2001/XMLSchema#string

Aregahegn Yifru

http://www.w3.org/2001/XMLSchema#string

Colin Osborne

http://www.w3.org/2001/XMLSchema#string

David McKenney

http://www.w3.org/2001/XMLSchema#string

Deborah Palestrant

http://www.w3.org/2001/XMLSchema#string

Donghui Yu

http://www.w3.org/2001/XMLSchema#string

Elin M Rann

http://www.w3.org/2001/XMLSchema#string

Gabriel Gamber

http://www.w3.org/2001/XMLSchema#string

P304

2376-2387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5106802

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM201685H

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Lewis Whitehead

P577

2012-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22315981

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile